Who are PHENTOLAMINE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Norepinephrine Bitartrate In 5% Dextrose, nebulized epinephrine and nebulized albuterol, ibuprofen; pseudoephedrine HCl, almotriptan or pseudoephedrine, Ibuprofen + Pseudoephedrine Hydrochloride, Nasal Decongestant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phentolamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PHENTOLAMINE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PHENTOLAMINE (PHENTOLAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed alpha-adrenergic receptors Small molecule Live · refreshed every 30 min

Target snapshot

PHENTOLAMINE (PHENTOLAMINE). OraVerse accelerates the reversal of soft-tissue anesthesia by causing vasodilation through alpha-adrenergic blockade.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PHENTOLAMINE TARGET	PHENTOLAMINE		marketed		alpha-adrenergic receptors	1952-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
nebulized epinephrine and nebulized albuterol	nebulized epinephrine and nebulized albuterol	Rambam Health Care Campus	marketed	Adrenergic agonist combination	Alpha-adrenergic receptors, Beta-2 adrenergic receptors
ibuprofen; pseudoephedrine HCl	ibuprofen; pseudoephedrine HCl	Johnson & Johnson Consumer and Personal Products Worldwide	marketed	NSAID + sympathomimetic decongestant combination	COX-1/COX-2 (ibuprofen); alpha-adrenergic receptors (pseudoephedrine)
almotriptan or pseudoephedrine	almotriptan or pseudoephedrine	Clinvest	marketed	Triptan + sympathomimetic decongestant combination	5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine)
Ibuprofen + Pseudoephedrine Hydrochloride	Ibuprofen + Pseudoephedrine Hydrochloride	Dr. Reddy's Laboratories Limited	marketed	NSAID + decongestant combination	COX-1/COX-2 (ibuprofen); alpha-adrenergic receptors (pseudoephedrine)
Nasal Decongestant	Nasal Decongestant	Engelhard Arzneimittel GmbH & Co.KG	marketed	Sympathomimetic decongestant	Alpha-adrenergic receptors (likely alpha-1)

Recent regulatory actions (last 90 days)

2026-03-26 — Norepinephrine Bitartrate In 5% Dextrose · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PHENTOLAMINE — Competitive Intelligence Brief. https://druglandscape.com/ci/phentolamine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing